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Objectives 
Macular oedema (MO) is an eye condition that can result in severe visual impairment. MO can be 
caused by central retinal vein occlusion (CRVO). The CRVO prevalence in the UK is estimated 
between 0.1% and 0.4%, with most patients (71%) being at least 65 years old. The objective of this 
study was to develop a conceptual model comparing bevacizumab, aflibercept and ranibizumab 
treatment for MO due to CRVO. The conceptual model would be used to inform a lifetime costs and 
QALYs decision model, which would incorporate data that will become available from the LEAVO 
trial. The LEAVO trial is a non-inferiority trial that compares these treatments. 
 
Methods 
A literature review was conducted to identify cost effectiveness models for MO due to CRVO. These 
were critiqued and the key limitations identified. A problem-orientated model and 2 decision-
orientated models (one discrete event simulation [DES] and one state-transition approach) were 
developed. 
 
Results 
Five cost-effectiveness models were identified, all of which used a state-transition approach. The 
limitations of these models included modelling one eye only, not accounting for injection frequency, 
modelling adverse events and effectiveness independently to injection frequency or number of prior 
injections, and not including fellow eye involvement. The conceptual DES model developed from this 
work could address more limitations in a simpler way than the conceptual state-transition approach. 
However, the DES approach is response based, requiring a lot of data to populate, which may not be 
possible with LEAVO trial data. 
 
Conclusions 
Many of the limitations of current decision models of treatments for MO due to CRVO could be 
addressed by taking a discrete event simulation approach. This approach may be limited by data 
availability. 
